Profluent Bio vs ConcertAI

Side-by-side comparison of AI visibility scores, market position, and capabilities

ConcertAI leads in AI visibility (74 vs 36)
Profluent Bio logo

Profluent Bio

EmergingBiotechnology

AI Protein Design

AI protein design company released OpenCRISPR-1, the first gene editor designed entirely by AI; raised $35M developing novel enzymes, antibodies, and gene-editing tools by exploring protein sequence space beyond what evolution has produced.

AI VisibilityBeta
Overall Score
D36
Category Rank
#94 of 198
AI Consensus
79%
Trend
stable
Per Platform
ChatGPT
40
Perplexity
33
Gemini
37

About

Profluent Bio is an AI protein design company founded in 2022 by former Meta AI researcher Ali Madani, raising $35M in seed and Series A funding. The company trains large generative models on biological sequence data to design novel proteins with specific structural and functional properties, analogous to how large language models generate text. Profluent made scientific history in 2024 by publishing OpenCRISPR-1, the first gene editor designed entirely by AI rather than adapted from natural organisms, which the company released open source for non-commercial research. The platform enables design of novel enzymes, antibodies, and gene-editing tools by exploring protein sequence space far beyond what evolution has produced. Profluent works with pharmaceutical and agricultural biotechnology companies that need custom protein tools for research and therapeutic development. The company represents a fundamental advance in moving protein engineering from directed evolution and rational design toward generative AI-driven discovery.

Full profile
ConcertAI logo

ConcertAI

LeaderLife Sciences & BioTech

Oncology AI & Real-World Data

ConcertAI is an oncology AI and real-world data company at a $1.9B valuation — 5.5M multi-modal cancer RWD records, $230M+ raised, exiting FY2024 profitable with mid-teens EBITDA margins.

AI VisibilityBeta
Overall Score
B74
Category Rank
#2 of 198
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
73
Perplexity
69
Gemini
70

About

ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates multi-modal patient data — including electronic health records, genomics, imaging, and pathology — from a network of oncology providers to support biopharma companies in clinical trial design, site selection, protocol optimization, patient matching, and regulatory submission.

Full profile

AI Visibility Head-to-Head

36
Overall Score
74
#94
Category Rank
#2
79
AI Consensus
80
stable
Trend
stable
40
ChatGPT
73
33
Perplexity
69
37
Gemini
70
32
Claude
70
38
Grok
77

Key Details

Category
AI Protein Design
Oncology AI & Real-World Data
Tier
Emerging
Leader
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Profluent Bio
AI Protein Design

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.